GSK Q3 Adjusted EPS $1.27 Beats $1.07 Estimate, Sales $10.27B Beat $9.37B Estimate
Portfolio Pulse from Benzinga Newsdesk
GSK reported Q3 earnings of $1.27 per share, beating the analyst consensus estimate of $1.07 by 18.69%. This is a 14.41% increase over earnings of $1.11 per share from the same period last year. The company also reported quarterly sales of $10.27 billion, beating the analyst consensus estimate of $9.37 billion by 9.55%. This is a 11.12% increase over sales of $9.24 billion the same period last year.
November 01, 2023 | 7:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's Q3 earnings and sales have surpassed analyst estimates, indicating a strong financial performance. This could potentially lead to a positive impact on the company's stock.
GSK's earnings and sales for Q3 have exceeded analyst estimates, which is a positive indicator of the company's financial health. This could potentially lead to increased investor confidence and a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100